Although the majority of patients with cystic fibrosis (CF) will be managed by specialty care, the primary care provider is often the first line of contact for many routine concerns. When encountering a patient with CF in the primary setting, there are extrapulmonary symptoms that must be considered in patients, which includes gastrointestinal symptoms.
Significant improvements in cystic fibrosis (CF) care have focused primarily on the pulmonary system, but addressing the gastrointestinal complications of CF presents a major opportunity for improvement in disease management.
Treatments for cystic fibrosis are evolving. Here’s a look at new CFTR modulator therapies including the most recent approval—elexacaftor/tezacaftor/ivacaftor (Trikafta).